AI Real-Time Blood Analyzer HemoScan FDA-Approved: Complete Blood Count and Anomaly Flagging in 30 Seconds
American blood diagnostics company SightDx launches portable AI blood analyzer HemoScan, completing full blood cell counting, classification, and anomaly flagging from a single drop of blood in 30 seconds, suitable for primary care and emergency settings.
American blood diagnostics company SightDx today announced FDA approval for its portable AI blood analyzer HemoScan. About the size of a smartphone, HemoScan requires just one fingertip blood drop (10 microliters) and uses a microfluidic chip with AI image analysis to complete full blood cell analysis — including white blood cell differential counts, red blood cell morphology analysis, and platelet counts — in 30 seconds.
Traditional blood analyzers require professional laboratory environments and trained operators, costing about $30 per test with 1-2 hour wait times. HemoScan's per-test consumable cost is just $2, operable by non-specialists, with results displayed instantly and synced via Bluetooth to physician workstations.
HemoScan is particularly suited for primary care clinics, remote medical stations, and emergency settings where rapid blood analysis results help physicians make critical decisions within minutes.
Disclaimer
Content is AI-generated. Do not use it as a basis for real decisions. Do not cite it as factual reporting.